Julian Moore
Family Medicine · Okeechobee, FLNPI 1437199494
Payments from drug & device makers
Across 98 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$342
- Almirall LLC$314
- Lilly USA, LLC$166
- Pfizer$127
- GSK$85
- Novartis$78
- plus $731 from 18 others
What the payments were for
- Food & beverage$1,843100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 13 | $342 |
| Almirall LLC | 19 | $314 |
| Lilly USA, LLC | 11 | $166 |
| Pfizer | 7 | $127 |
| GSK | 5 | $85 |
| Novartis | 3 | $78 |
| AbbVie | 4 | $71 |
| Amgen | 4 | $66 |
| Lundbeck LLC | 3 | $66 |
| Sun Pharmaceutical Industries Inc. | 3 | $59 |
| AstraZeneca | 3 | $59 |
| EPI Health, LLC | 3 | $53 |
| Mannkind Corporation | 3 | $48 |
| Exact Sciences | 2 | $47 |
| Insulet Corporation | 2 | $43 |
| Astellas Pharma US Inc | 3 | $41 |
| Abbott | 2 | $41 |
| Gilead | 2 | $26 |
| Novo Nordisk | 1 | $23 |
| Biofrontera Inc. | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Johnson & Johnson | 1 | $14 |
How this compares
$1,843 in reported general payments places this provider in the 70th percentile of 7,282 family medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 67 | $76,692 |
| EliquisApixaban | 49 | $45,238 |
| JanuviaSitagliptin Phosphate | 54 | $41,612 |
| TrulicityDulaglutide | 32 | $31,503 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $19,945 |
| FarxigaDapagliflozin Propanediol | 12 | $6,603 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $6,165 |
| JardianceEmpagliflozin | 11 | $5,113 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $3,879 |
| Levemir FlexpenInsulin Detemir | 14 | $3,118 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 60 | $2,240 |
| Ezetimibe | 48 | $1,638 |
| Ventolin HfaAlbuterol Sulfate | 21 | $1,278 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $1,257 |
| Gabapentin | 65 | $762 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $23 | $76,69267 claims |
| PfizerEliquis | $127 | $45,23849 claims |
| Lilly USA, LLCTrulicity | $166 | $31,50332 claims |
| GSKTrelegy Ellipta | $85 | $19,94524 claims |
| AstraZenecaFarxiga, Symbicort | $59 | $10,48227 claims |
| AbbVieSynthroid | $71 | $46711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Okeechobee
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.